Query author contributions in Reactome Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome .
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Phosphorylated heterodimers of ERBB2 KD mutants recruit GRB2:SOS1 through SHC1
Class:Id Reaction:9664983 _displayName Phosphorylated heterodimers of ERBB2 KD mutants recruit GRB2:SOS1 through SHC1 _doRelease TRUE _timestamp 2019-11-12 18:16:25 authored [InstanceEdit:9656339] Orlic-Milacic, Marija, 2019-07-31 compartment [Compartment:876] plasma membrane created [InstanceEdit:9664982] Orlic-Milacic, Marija, 2019-10-28 disease [Disease:1500689] cancer edited [InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01 entityFunctionalStatus [EntityFunctionalStatus:9664980] gain_of_function of Phosphorylated heterodimers of ERBB2 KD mutants:p-Y349,Y350-SHC1 [plasma membrane] input [Complex:9664975] Phosphorylated heterodimers of ERBB2 KD mutants:p-Y349,Y350-SHC1 [plasma membrane] [Homo sapiens] [Complex:109797] GRB2-1:SOS1 [cytosol] [Homo sapiens] isChimeric FALSE literatureReference [LiteratureReference:9665642] HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors [LiteratureReference:9649397] Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib [LiteratureReference:9646776] EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation [LiteratureReference:9646435] Activating HER2 mutations in HER2 gene amplification negative breast cancer [LiteratureReference:9646787] Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) [LiteratureReference:9646758] Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification [LiteratureReference:9650849] Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations [LiteratureReference:9647026] An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer [LiteratureReference:9652195] Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2 [LiteratureReference:9664473] Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism [LiteratureReference:9646962] Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity [LiteratureReference:9646964] Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor modified [InstanceEdit:9665666] Orlic-Milacic, Marija, 2019-10-31 [InstanceEdit:9666039] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666040] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666041] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666042] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9667512] Orlic-Milacic, Marija, 2019-11-12 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08 name Phosphorylated heterodimers of ERBB2 KD mutants recruit GRB2:SOS1 through SHC1 normalReaction
output [Complex:9664981] Phosphorylated heterodimers of ERBB2 KD mutants:p-Y349,Y350-SHC1:GRB2:SOS1 [plasma membrane] [Homo sapiens] precedingEvent
releaseDate 2019-12-10 reviewed [InstanceEdit:9662685] Kancha, Rama Krishna, 2019-09-16 reviewStatus [ReviewStatus:9821382] five stars species [Species:48887] Homo sapiens stableIdentifier [StableIdentifier:9664985] R-HSA-9664983.2 summation [Summation:9664984] For the following ERBB2 KD mutants that were shown to activa... (hasEvent) [Pathway:9664565] Signaling by ERBB2 KD Mutants [Homo sapiens] (precedingEvent) [Reaction:9664991] RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 KD mutants [Homo sapiens] (updatedInstance) [_UpdateTracker:9835786] Update Tracker - [Reaction:9664983] Phosphorylated heterodimers of ERBB2 KD mutants recruit GRB2:SOS1 through SHC1 - v85:[modifyText]
[Change default viewing format]
List...
Protein identifiers
ChEBI identifiers
KEGG COMPOUND identifiers
No pathways have been reviewed or authored by Phosphorylated heterodimers of ERBB2 KD mutants recruit GRB2:SOS1 through SHC1 (9664983)
